IP Verse

Compositions And Methods For Growth Factor Modulation - EP2981822

The patent EP2981822 was granted to Scholar Rock on Sep 2, 2020. The application was originally filed on May 6, 2014 under application number EP14795041A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2981822

SCHOLAR ROCK
Application Number
EP14795041A
Filing Date
May 6, 2014
Status
Granted And Under Opposition
Jul 31, 2020
Grant Date
Sep 2, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CHUGAI SEIYAKU KABUSHIKI KAISHAJun 1, 2021SIMMONS & SIMMONS MUNICHADMISSIBLE

Patent Citations (43) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0404097
DESCRIPTIONUS2010009424
DESCRIPTIONUS2010196983
DESCRIPTIONUS2011008364
DESCRIPTIONUS2011053221
DESCRIPTIONUS2011135570
DESCRIPTIONUS2013122007
DESCRIPTIONUS4179337
DESCRIPTIONUS4301144
DESCRIPTIONUS4485045
DESCRIPTIONUS4496689
DESCRIPTIONUS4544545
DESCRIPTIONUS4640835
DESCRIPTIONUS4670417
DESCRIPTIONUS4791192
DESCRIPTIONUS5013556
DESCRIPTIONUS5024947
DESCRIPTIONUS5116964
DESCRIPTIONUS5208020
DESCRIPTIONUS5475092
DESCRIPTIONUS5541087
DESCRIPTIONUS5585499
DESCRIPTIONUS5846545
DESCRIPTIONUS6348584
DESCRIPTIONUS6492497
DESCRIPTIONUS6673901
DESCRIPTIONUS7151169
DESCRIPTIONUS7572599
DESCRIPTIONUS7723486
DESCRIPTIONUS8415459
DESCRIPTIONUS8637637
DESCRIPTIONWO2011034935
DESCRIPTIONWO2011151432
DESCRIPTIONWO9311161
INTERNATIONAL-SEARCH-REPORTUS2008038748
INTERNATIONAL-SEARCH-REPORTUS2011053221
OPPOSITIONEP2193805
OPPOSITIONJPH05336990
OPPOSITIONUS2006062763
OPPOSITIONWO2011102483
OTHERJPH05336990
OTHERWO2011102483
OTHERWO2014074532

Non-Patent Literature (NPL) Citations (165) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALDERSON, K.L. et al., J Biomed Biotechnol., (20110000), page 379123-
DESCRIPTION- ALTSCHUL, S. F. et al., J. Molec. Biol., (19900000), vol. 215, page 403-
DESCRIPTION- ANDERSON et al., J Biol Chem., (20070000), vol. 283, no. 11, pages 25852 - 35-
DESCRIPTION- ANDRE, F.M. et al., "Nucleic acids electrotransfer in vivo: mechanisms and practical aspects", Curr Gene Ther., (20100000), vol. 10, pages 267 - 80-
DESCRIPTION- AURIGEMMA, N Engl J Med., (20060000), vol. 355, no. 3, pages 308 - 10-
DESCRIPTION- BAZIGOU, E. et al., "Integrin- a9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis", Dev Cell, (20090800), vol. 17, no. 2, pages 175 - 86-
DESCRIPTION- BENOIT, D.S. et al., "Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery", Biomacromolecules, (20110000), vol. 12, pages 2708 - 14-
DESCRIPTION- BERGE et al., Journal of Pharmaceutical Science, (19770000), vol. 66, pages 1 - 19-
DESCRIPTION- BISWAS et al., J Clin Invest, (20070500), vol. 117, no. 5, pages 1305 - 1313-
DESCRIPTION- BLOBE, G.C. et al., "Role of transforming growth factor beta in human disease", N Engl J Med., (20000504), vol. 342, no. 18, pages 1350 - 8-
DESCRIPTION- BOILEAU et al., Nature Genetics Letters, (20120000), vol. 44, no. 8, pages 916 - 23-
DESCRIPTION- CARILLO, H.LIPMAN, D., SIAM J Applied Math., (19880000), vol. 48, page 1073-
DESCRIPTION- CARON, N.J. et al., "Intracellular delivery of a Tat-eGFP fusion protein into muscle cells", Mol Ther., (20010000), vol. 3, no. 3, pages 310 - 8-
DESCRIPTION- CECO, E. et al., FEBS J., (20130000), vol. 280, no. 17, pages 4198 - 209-
DESCRIPTION- CHIARELLA, P. et al., "Application of electroporation in DNA vaccination protocols", Curr Gene Ther., (20100000), vol. 10, pages 281 - 6-
DESCRIPTION- COIN, P.G. et al., Am J Respir Crit Care Med., (19960000), vol. 154, no. 5, pages 1511 - 9-
DESCRIPTION- CZAJKOWSKY, D.M. et al., EMBO Mol Med., (20120000), vol. 4, no. 10, pages 1015 - 28-
DESCRIPTION- DENICOURT, C. et al., "Another twist in the transforming growth factor β-induced cell-cycle arrest chronicle", PNAS, (20030000), vol. 100, no. 26, pages 15290 - 1-
DESCRIPTION- DEVEREUX, J. et al., Nucleic Acids Research, (19840000), vol. 12, no. 1, page 387-
DESCRIPTION- EPPSTEIN, D.A. et al., "Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor", Proc Natl Acad Sci USA., (19850600), vol. 82, no. 11, pages 3688 - 92-
DESCRIPTION- FINKENSTEDT et al., British Journal of Haematology, (20080000), vol. 144, pages 789 - 93-
DESCRIPTION- FUJII, T. et al., BMC Gastroenterology, (20100000), vol. 10, page 79-
DESCRIPTION- FULLER et al., Invest Ophthalmol Vis Sci., (20090000), vol. 50, no. 12, pages 5759 - 68-
DESCRIPTION- GARDENGHI et al., JCI, (20100000), vol. 120, no. 12, pages 4466 - 77-
DESCRIPTION- GE et al., Mol Cel Biol., (20050000), vol. 25, no. 14, pages 5846 - 58-
DESCRIPTION- GE et al., Mol Cell Biol., (20050000), vol. 25, no. 14, pages 5846 - 58-
DESCRIPTION- GREENBERG, Curr Opin Neurol., (20120000), vol. 25, no. 5, pages 630 - 9-
DESCRIPTION- G. S. BANKER, Modern Pharmaceutics, Drugs and the Pharmaceutical Sciences, Marcel Dekker, (19960000), vol. 72-
DESCRIPTION- GUO et al., Diabetes, (20120000), vol. 61, no. 10, pages 2414 - 23-
DESCRIPTION- HAHM, K. et al., Am J Pathol., (20070000), vol. 170, no. 1, pages 110 - 5-
DESCRIPTION- HAN et al., Int J Biochem Cell Biol., (20130000), vol. 45, no. 10, pages 2333 - 47-
DESCRIPTION- HILL, J.J. et al., JBC, (20020000), vol. 277, no. 43, pages 40735 - 41-
DESCRIPTION- HILL, J.J. et al., Mol Endocrinology., (20030000), vol. 17, no. 6, pages 1144 - 54-
DESCRIPTION- HOLLINGER, P. et al., "Diabodies'':Small bivalent and bispecific antibody fragments", PNAS, (19930000), vol. 90, pages 6444 - 8-
DESCRIPTION- HORAN G.S. et al., Am J Respir Crit Care Med., (20071004), vol. 177, no. 1, pages 56 - 65-
DESCRIPTION- HSIAO et al., Mol Cell Biol., (20000000), vol. 20, no. 10, pages 3742 - 51-
DESCRIPTION- HUH, M.I. et al., "Distribution of TGF-β isoforms and signaling intermediates in corneal fibrotic wound repair", J Cell Biochem., (20091001), vol. 108, no. 2, pages 476 - 88-
DESCRIPTION- HWANG, K.J. et al., "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study", Proc Natl Acad Sci USA., (19800700), vol. 77, no. 7, pages 4030 - 4-
DESCRIPTION- IREDALE, J.P, J Clin Invest., (20070000), vol. 117, no. 3, pages 539 - 48-
DESCRIPTION- JANSSENS, K. et al., "Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein", J Biol Chem., (20021218), vol. 278, no. 9, pages 7718 - 24-
DESCRIPTION- KATSIMPARDI, L. et al., Science Express, (20140000), pages 2 - 6-
DESCRIPTION- KLAMPF et al., NEJM, (20130000), vol. 369, pages 2379 - 90-
DESCRIPTION- KOEPKE, M.L. et al., Nephrol Dial Transplant., (20070000), vol. 22, no. 4, pages 1062 - 9-
DESCRIPTION- LACOUT, C. et al., Blood, (20060000), vol. 107, no. 5, pages 2952 - 60-
DESCRIPTION- LEE et al., PNAS, (20130000), vol. 110, no. 39, pages E3713 - 22-
DESCRIPTION- LEE, Immunol Endocr Metab Agents Med Chem., (20100000), vol. 10, pages 183 - 94-
DESCRIPTION- LEE, S-J. et al., Mol Endocrinol., (20100000), vol. 24, no. 10, pages 1998 - 2008-
DESCRIPTION- LING, H. et al., J Am Soc Nephrol., (20030000), vol. 14, pages 377 - 88-
DESCRIPTION- LOFFREDO et al., Cell, (20130000), vol. 153, pages 828 - 39-
DESCRIPTION- MA et al., J Clin Invest., (20050000), vol. 115, pages 3460 - 72-
DESCRIPTION- MA, L.J. et al., American Journal of Pathology, (20030000), vol. 163, no. 4, pages 1261 - 73-
DESCRIPTION- MARTIN, F.J. et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting", J Biol Chem., (19820110), vol. 257, no. l, pages 286 - 8, XP001098117-
DESCRIPTION- MARVIN, J.S. et al., Acta Pharmacologica Sinica, (20050000), vol. 26, no. 6, pages 649 - 58-
DESCRIPTION- MASCARENHAS, J. et al., Leukemia and Lymphoma, (20140000), vol. 55, pages 450 - 2-
DESCRIPTION- MASSAGUE, Nature Reviews Molecular Cell Biology, (20000000), vol. 1, pages 169 - 78-
DESCRIPTION- MASSIGNANI, M. et al., "Cellular delivery of antibodies: effective targeted subcellular imaging and new therapeutic tool", Nature Proceedings, (20100000), page l-17-
DESCRIPTION- MCNAUGHTON, B.R. et al., "Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins", Proc Natl Acad Sci, USA, (20090000), vol. 106, pages 6111 - 6-
DESCRIPTION- MCPHERRON et al., Adipocyte, (20130000), vol. 2, no. 2, pages 92 - 8-
DESCRIPTION- MENG, X.M. et al., "Smad2 Protects against TGF-beta/Smad3-Mediated Renal Fibrosis", J Am Soc Nephrol., (20100701), vol. 21, no. 9, pages 1477 - 87-
DESCRIPTION- MEYERSMILLER, CABIOS, (19890000), vol. 4, pages 11 - 17-
DESCRIPTION- MORELY, Family Practice, (20120000), vol. 29, pages i44 - i48-
DESCRIPTION- MULLALLY, A. et al., Cancer Cell, (20100000), vol. 17, pages 584 - 96-
DESCRIPTION- NEWMAN, C.M. et al., "Gene therapy progress and prospects: ultrasound for gene transfer", Gene Ther., (20070000), vol. 14, no. 6, pages 465 - 75-
DESCRIPTION- NIALS, A.T. et al., Disease Models and Mechanisms, (20080000), vol. 1, pages 213 - 20-
DESCRIPTION- ODENIKE, O., Hematology, (20130000), vol. 1, no. 545-52-
DESCRIPTION- OIDA, T. et al., "TGF-β induces surface LAP expression on Murine CD4 T cells independent of FoxP3 induction", PLOS One, (20100000), vol. 5, no. ll, page el5523-
DESCRIPTION- PALMER, E.L. et al., "Sequence and tissue distribution of the integrin a subunit, a novel partner of β1 that is widely distributed in epithelia and muscle", Journal of Cell Biology, (19930000), vol. 123, no. 5, pages 1289 - 97, XP002305856-
DESCRIPTION- PAULUHN, J. et al., Toxicology, (20010000), vol. 161, pages 153 - 63-
DESCRIPTION- PICHT, G. et al., "Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development", Graefes Arch Clin Exp Ophthalmol., (20010323), vol. 9, no. 3, pages 199 - 207-
DESCRIPTION- POSTEMA, M. et al., "Ultrasound-directed drug delivery", Curr Pharm Biotechnol., (20070000), vol. 8, pages 355 - 61-
DESCRIPTION- PREUSCH et al., Eur J Med Res., (20130000), vol. 18, page 19-
DESCRIPTION- Remington's Pharmaceutical Sciences, Mack Publishing Company, (19850000), page 1418-
DESCRIPTION- RIETHMULLER, G., Cancer Immunity, (20120000), vol. 12, pages 12 - 18-
DESCRIPTION- ROBERTS, S.N. et al., J Pathol., (19950000), vol. 176, no. 3, pages 309 - 18-
DESCRIPTION- RODINO-KLAPAC, L.R. et al., Muscle Nerve, (20090000), vol. 39, no. 3, pages 283 - 96-
DESCRIPTION- ROZEMA, D.B. et al., "Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes", Proc Natl Acad Sci USA., (20070000), vol. 104, pages 12982 - 12887-
DESCRIPTION- SASU et al., Blood, (20100000), vol. 115, no. 17, pages 3616 - 24-
DESCRIPTION- SCHAEFER, D.W. et al., Eur Respir Rev., (20110000), vol. 20, no. 120, pages 85 - 97-
DESCRIPTION- SCHAEFER, W. et al., PNAS, (20110000), vol. 108, no. 27, pages 11187 - 92-
DESCRIPTION- SENGLE et al., J Biol Chem., (20110000), vol. 286, no. 49, pages 41905 - 99-
DESCRIPTION- SENGLE et al., J Mol Biol., (20080000), vol. 381, no. 4, pages 1025 - 39-
DESCRIPTION- SHERWOOD, J.K. et al., "Controlled antibody delivery systems", Nature Biotechnology, (19920000), vol. 10, pages 1446 - 9-
DESCRIPTION- SMITH et al., Circ Res., (19990000), vol. 84, no. 10, pages 1212 - 22-
DESCRIPTION- STANISZEWSKA, I. et al., "Integrin α β is a receptor for nerve growth factor and other neurotrophins", Journal of Cell Science, (20070000), vol. 121, pages 504 - 13-
DESCRIPTION- SUMIOKA, T. et al., "Inhibitory effect of blocking TGF-beta/Smad signal on injury-induced fibrosis of corneal endothelium", Mol Vis., (20081211), vol. 14, pages 2272 - 81, XP008148116-
DESCRIPTION- TAKEHARA-KASAMATSU, Y. et al., J Med Invest., (20070000), vol. 54, no. 3-4, pages 276 - 88-
DESCRIPTION- TANNO et al., Curr Opin Hematol., (20100000), vol. 17, no. 3, pages 184 - 90-
DESCRIPTION- TAYLOR, R.G. et al., Lab Invest., (19850000), vol. 52, no. l, pages 61 - 70-
DESCRIPTION- T. E. CREIGHTON, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., (19830000), pages 79 - 86-
DESCRIPTION- THIES, R.S. et al., "GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding", Growth Factors, (20010000), vol. 18, pages 251 - 9, XP008013942-
DESCRIPTION- T. HIGUCHIV. STELLA, "Pro-drugs as Novel Delivery Systems", A.C.S. Symposium Series, vol. 14-
DESCRIPTION- THOMAS, M. et al., Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation, (20000000), vol. 275, no. 51, pages 40235 - 43-
DESCRIPTION- THRALL, R.S. et al., Am J Pathol., (19790000), vol. 95, pages 117 - 30-
DESCRIPTION- TRAN, D.Q. et al., "GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells", PNAS, (20090000), vol. 106, no. 32, doi:10.1073/pnas.0901944106, pages 13445 - 50, XP055021925-
DESCRIPTION- TRAN, D.Q. et al., "GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells", PNAS, (20090602), vol. 106, no. 32, doi:10.1073/pnas.0901944106, pages 13445 - 50, XP055021925-
DESCRIPTION- TRIPATHI, R.C. et al., "Aqueous humor in glaucomatous eyes contains an increased level of TGF-Ø2", Exp Eye Res., (19941205), vol. 9, no. 6, pages 723 - 7-
DESCRIPTION- TSANG, M. et al., Cytokine, (19950000), vol. 7, no. 5, pages 389 - 97-
DESCRIPTION- VANNUCCHI, A.M. et al., Blood, (20020000), vol. 100, no. 10, pages 3495 - 503-
DESCRIPTION- VLAHOS, R. et al., Clin Sci., (20140000), vol. 126, pages 253 - 65-
DESCRIPTION- WANG, A. et al., Expression of the integrin subunit a in the murine embryo. Developmental Dynamics, (19950000), vol. 204, pages 421 - 31-
DESCRIPTION- WANG, R. et al., "GARP regulates the bioavailability and activation of TGF-β", Mol Biol Cell., (20120125), vol. 23, no. 6, pages 1129 - 39-
DESCRIPTION- WI, J. et al., Hepatology, (20110000), vol. 53, no. 4, pages 1342 - 51-
DESCRIPTION- WOLFMAN, N.M. et al., PNAS, (20031006), vol. 100, no. 26, pages 15842 - 6-
DESCRIPTION- XU et al., Matrix Biol., (20100000), vol. 29, no. 6, pages 461 - 70-
DESCRIPTION- YOON, C.S. et al., "Ultrasound-mediated gene delivery", Expert Opin Drug Deliv., (20100000), vol. 7, pages 321 - 30-
DESCRIPTION- YU, A.L. et al., "TGF-Ø2 induces senescence-associated changes in human trabecular meshwork cells", Invest Ophthalmol Vis Sci., (20101105), vol. 1, no. 11, pages 5718 - 23-
DESCRIPTION- ABE, M. et al., "An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct", Analytical Biochemistry, (19940000), vol. 216, doi:10.1006/abio.1994.1042, pages 276 - 84, XP024763357
DESCRIPTION- OLIVA, B. et al., "An automated classification of the structure of protein loops", J Mol Biol., (19970000), vol. 266, no. 4, doi:10.1006/jmbi.1996.0819, pages 814 - 30, XP004462194
DESCRIPTION- DESHAYES, S. et al., "Cell-penetrating peptides: tools for intracellular delivery of therapeutics", Cell Mol Life Sci., (20050000), vol. 62, no. 16, doi:10.1007/s00018-005-5109-0, pages 1839 - 49, XP019200807
DESCRIPTION- VERDINE, G.L. et al., "Stapled peptides for intracellular drug targets", Methods Enzymol., (20120000), vol. 503, doi:10.1016/B978-0-12-396962-0.00001-X, pages 3 - 33, XP055042537
DESCRIPTION- DAUGHERTY et al., "Formulation and delivery issues for monoclonal antibody therapeutics", Adv Drug Deliv Rev., (20060807), vol. 58, no. 5-6, doi:10.1016/j.addr.2006.03.011, pages 686 - 706, XP024892149
DESCRIPTION- PITELLA, F. et al., "Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity", Biomaterials, (20110000), vol. 32, doi:10.1016/j.biomaterials.2010.12.057, pages 3106 - 14, XP028145194
DESCRIPTION- CRONICAN, J.J. et al., "Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein", ACS Chem Biol., (20100000), vol. 5, doi:10.1021/cb1001153, pages 747 - 52, XP055242284
DESCRIPTION- DAVIS, M.E. et al., "The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic", Mol Pharm., (20090000), vol. 6, doi:10.1021/mp900015y, pages 659 - 668, XP055144106
DESCRIPTION- CASH, J.N et al., "The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding", The EMBO Journal, (20090000), vol. 28, doi:10.1038/emboj.2009.205, pages 2662 - 76, XP055183670
DESCRIPTION- DAVIS, M.E. et al., "Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles", Nature, (20100000), vol. 464, doi:10.1038/nature08956, pages 1067 - 70, XP055094641
DESCRIPTION- SHI, M. et al., "Latent TGF-beta structure and activation", Nature, (20110615), vol. 474, no. 7351, doi:10.1038/nature10152, pages 343 - 9, XP055167968
DESCRIPTION- SHI, M. et al., "Latent TGF-fJ structure and activation", Nature, (20110615), vol. 474, no. 7351, doi:10.1038/nature10152, pages 343 - 9, XP055167968
DESCRIPTION- SHI, M. et al., "Latent TGF-P structure and activation", Nature, (20110615), vol. 474, no. 7351, doi:10.1038/nature10152, pages 343 - 9, XP055167968
DESCRIPTION- OKLU, R. et al., "The latent transforming growth factor beta binding protein (LTBP) family", Biochem J., (20001215), vol. 352, doi:10.1042/0264-6021:3520601, pages 601 - 10, XP009010129
DESCRIPTION- SIEGWART, D.J. et al., "Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery", Proc Natl Acad Sci USA., (20110000), vol. 108, doi:10.1073/pnas.1106379108, pages 12996 - 3001, XP055454058
DESCRIPTION- YOKASAKI, Y. et al., "Identification of the ligand binding site for the integrin α β in the third fibronectin type III repeat of tenascin C", The Journal of Biological Chemistry, (19980000), vol. 273, no. 19, doi:10.1074/jbc.273.19.11423, pages 11423 - 8, XP055032169
DESCRIPTION- YOKOSAKI, Y. et al., "The integrin α β binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin", JBC, (19990000), vol. 274, no. 51, doi:10.1074/jbc.274.51.36328, pages 36328 - 34, XP002953833
DESCRIPTION- MARCINKIEWICZ, C. et al., "Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin α β with VCAM-1, tenascin-C, and osteopontin", JBC, (20000000), vol. 275, no. 41, doi:10.1074/jbc.M003209200, pages 31930 - 7, XP001020781
DESCRIPTION- OOMMEN, S. et al., "Vacular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin α β", JBC, (20110000), vol. 286, no. 2, doi:10.1074/jbc.M110.175158, pages 1083 - 92, XP055472312
DESCRIPTION- SATO-NISHIUCHI, R. et al., "Polydom/SVEPI is a ligand for integrin α β", JBC, (20120000), vol. 287, no. 30, doi:10.1074/jbc.M112.355016, pages 25615 - 30, XP055261550
DESCRIPTION- DAOPIN, S. et al., "Crystal structure of transforming growth factor-Ø2: an unusual fold for the superfamily", Science, (19920000), vol. 257, no. 5068, doi:10.1126/science.1631557, pages 369 - 73, XP000857489
DESCRIPTION- MEAD, A.L. et al., "Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery", Invest Ophthalmol Vis Sci., (20030800), vol. 44, no. 8, doi:10.1167/iovs.02-0978, pages 3394 - 401, XP002977767
DESCRIPTION- CARRINGTON, L.M. et al., "Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors", Invest Ophthalmol Vis Sci., (20060500), vol. 47, no. 5, doi:10.1167/iovs.05-0635, pages 1886 - 94, XP055504563
DESCRIPTION- MOHAMMAD, K.S. et al., "Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone", PLoS One, (20080416), vol. 4, no. 4, doi:10.1371/journal.pone.0005275, page e5275, XP055315063
DESCRIPTION- EL-ANDALOUSSI, S. et al., "Cell-penetrating peptides: mechanisms and applications", Curr Pharm Des., (20030000), vol. 11, no. 28, doi:10.2174/138161205774580796, pages 3597 - 611, XP008081641
DESCRIPTION- HOJMAN, P., "Basic principles and clinical advancements of muscle electrotransfer", Curr Gene Ther., (20100000), vol. 10, doi:10.2174/156652310791110994, pages 128 - 38, XP009185948
INTERNATIONAL-SEARCH-REPORT- "latent-transforming growth factor beta-binding protein 3 isoform 1 precursor [Homo sapiens]", GENBANK, (20130417), Database accession no. NP_001123616.1, URL: NCBI, XP055289926-
INTERNATIONAL-SEARCH-REPORT- PENTTINEN ET AL., "Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta.", J CELL SCI, (20020901), vol. 115, no. 17, pages 3457 - 3468, XP055289911-
INTERNATIONAL-SEARCH-REPORT- BISWAS ET AL., "Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.", J CLIN INVEST, (200705), vol. 117, no. 5, pages 1305 - 1313, XP055155586
OPPOSITION- Anonymous, "human lap (tgf-beta 1) antibody 27232 MAB2463", R&D systems, (20210512), page 1, XP055814047-
OPPOSITION- Anonymous, "human lap (tgf-beta 1) antibody 27235 MAB246", R&D systems, (20210512), page 1, XP055814040-
OPPOSITION- Anonymous, "Quantikine™ ELISA Human/Mouse/Rat/Porcine/Canine TGF-β1 Immunoassay Catalog Number DB100C Catalog Number SB100C Catalog Number PDB100C", (20220101), (20231222), XP093115005-
OPPOSITION- Anonymous, "R&D; Systems - Products", R&D systems, (20111025), pages 1 - 1, R&D systems, URL: https://web.archive.org/web/20111025114513/http:/rndsystems.com/product_results.aspx?m=2152&c=6, (20210615), XP055814057-
OPPOSITION- Anonymous, "Ultra-LEAF™ Purified anti-mouse/human LAP (TGF-β1) Antibody", BioLegend - Technical Data Sheet, (20140827), BioLegend - Technical Data Sheet, URL: https://d1spbj2x7qk4bg.cloudfront.net/fr-ch/products/ultra-leaf-purified-anti-mouse-human-lap-tgf-beta1-antibody-9009?pdf=true&displayInline=true&leftRightMargin=15&topBottomMargin=15&filename=Ultra-LEAF%E2%84%A2%20Purified%20anti-mouse/human%20LAP%20(TGF-%CE%B21)%20Antibody.pdf&v=20240814063131, XP093195942-
OPPOSITION- Miyazono Kohei, Hellman Ulf, Wernstedt Christer, Heldins Carl-Henrik, "Latent High Molecular Weight Complex of Transforming Growth Factor beta 1 PURIFICATION FROM HUMAN PLATELETS AND STRUCTURAL CHARACTERIZATION", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19880305), pages 6407 - 6415, THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20210615), XP055814005-
OPPOSITION- Miyazono Kohei, "Review The basis of Angiogenesis and Remodeling", Nihon Yakurigaku Zasshi Folia Pharmacol. Jpn., (19960101), vol. 107, no. 3, pages 133 - 140, XP055813999-
OPPOSITION- Birebent Brigitte, Et Al, "Suppressive properties of human CD4+CD25+ regulatory T?cells are dependent on CTLA-4 expression", European Journal of Immunology, Wiley VCH, Weinheim, Weinheim, (20041201), vol. 34, no. 12, doi:10.1002/eji.200324632, ISSN 0014-2980, pages 3485 - 3496, XP055814060
OPPOSITION- STOCKIS, J. et al., "Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg", Eur. J. Immu- nol., (20090000), vol. 39, doi:10.1002/eji.200939684, pages 3315 - 3322, XP055094846
OPPOSITION- Winter, G. ; Harris, W.J., "Humanized antibodies", TRENDS IN PHARMACOLOGICAL SCIENCES., ELSEVIER, HAYWARTH., GB, GB , (19930501), vol. 14, no. 5, doi:10.1016/0165-6147(93)90197-R, ISSN 0165-6147, pages 139 - 143, XP025809488
OPPOSITION- Minlong Shi, Jianghai Zhu, Rui Wang, Xing Chen, Lizhi Mi, Thomas Walz, Timothy A. Springer, "Latent TGF-&bgr; structure and activation", Nature, Macmillan Journals Ltd., etc., vol. 474, no. 7351, doi:10.1038/nature10152, ISSN 0028-0836, pages 343 - 349, XP055167968
OPPOSITION- MOUNTAIN A., ADAIR J. R., "ENGINEERING ANTIBODIES FOR THERAPY.", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, INTERCEPT LTD., ANDOVER, GB, GB , (19920101), vol. 10, no. 1, doi:10.1080/02648725.1992.10647886, ISSN 0264-8725, pages 1 - 142, XP000944337
OPPOSITION- Schuster Christopher, Et Al, "HLA-DR+ leukocytes acquire CD1 antigens in embryonic and fetal human skin and contain functional antigen-presenting cells", Journal of Experimental Medicine, Rockefeller University Press, US, US, (20090116), vol. 206, no. 1, doi:10.1084/jem.20081747, ISSN 0022-1007, pages 169 - 181, XP055814073
OPPOSITION- Sandra Boswell, Shayan Sharif, Akeel Alisa, Stephen P. Pereira, Roger Williams, Shahriar Behboudi, "Induction of latency-associated peptide (transforming growth factor-β1) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-α production in a transforming growth factor-β-dependent manner : Anti-inflammatory effects of LAP inducing ligand", Immunology, Wiley-Blackwell Publishing Ltd., GB, GB, (20110701), vol. 133, no. 3, doi:10.1111/j.1365-2567.2011.03425.x, ISSN 0019-2805, pages 278 - 287, XP055475426
OPPOSITION- GODFREY W.R. et al., "Cord blood CD 4+ CD 25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function", Blood, (20050000), vol. 105, no. Issue 2, doi:10.1182/blood-2004-06-2467, pages 750 - 758, XP055662876
OPPOSITION- Takatoku Oida, Howard L. Weiner, "TGF-β Induces Surface LAP Expression on Murine CD4 T Cells Independent of Foxp3 Induction", PLoS ONE, (20101124), vol. 5, no. 11, doi:10.1371/journal.pone.0015523, page e15523, XP055475471
OPPOSITION- Oida Takatoku, Weiner Howard L., "Murine CD4 T Cells Produce a New Form of TGF-β as Measured by a Newly Developed TGF-β Bioassay", PLOS ONE, Public Library of Science, US, US , (20110411), vol. 6, no. 4, doi:10.1371/journal.pone.0018365, ISSN 1932-6203, page e18365, XP093195939
OPPOSITION- HOOGENBOOM H.R., "Overview of Antibody Phage-Display Technology and Its Applications", Antibody Phage Display. Methods in Molecular BiologyTM, vol. 178, doi:10.1385/1-59259-240-6:001, (20020000), pages 1 - 37, URL: https://doi.org/10.1385/1-59259- 240-6: 001, XP009065679
OPPOSITION- Prassler J; Steidl S; Urlinger S, "In vitro affinity maturation of HuCAL antibodies: Complementarity determining region exchange and RapMAT technology", Immunotherapy, Future Medicine Ltd, UK, UK, (20090701), vol. 1, no. 4, doi:10.2217/IMT.09.23, ISSN 1750-743X, pages 571 - 583, XP001525666
OPPOSITION- Almagro Juan C; Fransson Johan, "Humanization of antibodies", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, US , (20080101), vol. 13, no. 5, doi:10.2741/2786, ISSN 1093-9946, pages 1619 - 1633, XP009126790
OPPOSITION- Linda K. Jolliffe, "HUMANIZED ANTIBODIES: ENHANCING THERAPEUTIC UTILITY THROUGH ANTIBODY ENGINEERING.", International Reviews of Immunology, Taylor & Francis, (19930101), vol. 10., no. 2-3, doi:10.3109/08830189309061699, ISSN 0883-0185, pages 241 - 250, XP000561185
OPPOSITION- Lonberg N; Huszar D, "Human antibodies from transgenic mice.", International Reviews of Immunology, Taylor & Francis, (19950101), vol. 13, no. 1, doi:10.3109/08830189509061738, ISSN 0883-0185, pages 65 - 93, XP002156616
OPPOSITION- Nakamura Kazuhiko, Kitani Atsushi, Fuss Ivan, Pedersen Aasta, Harada Naohiko, Nawata Hajime, Strober Warren, "TGF-β1 Plays an Important Role in the Mechanism of CD4 + CD25 + Regulatory T Cell Activity in Both Humans and Mice", The Journal of Immunology, Williams & Wilkins Co., US, US, (20040115), vol. 172, no. 2, doi:10.4049/jimmunol.172.2.834, ISSN 0022-1767, pages 834 - 842, XP055814069
OTHER- WHO Drug Information, (20090000), vol. 23, no. 2-
SEARCH- KANZAKI TETSUTO ET AL, "Latent transforming growth factor-beta binding protein-1, a component of latent transforming growth factor-beta complex, accelerates the migration of aortic smooth muscle cells in diabetic rats through integrin-beta3.", DIABETES, (200303), vol. 52, no. 3, ISSN 0012-1797, pages 824 - 828, XP002761961 [X] 1,7-9,13-15 * abstract * * Antibody page 825 *-
SEARCH- MAEDA S ET AL, "The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3)", CALCIFIED TISSUE INTERNATIONAL, (200201), vol. 70, no. 1, ISSN 0171-967X, pages 54 - 65, XP002761962 [X] 1,7-9,13-15 * abstract * * page 57, column r, paragraph 1 *
SEARCH- DREWS F ET AL, "Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1783, no. 1, doi:10.1016/J.BBAMCR.2007.08.004, ISSN 0167-4889, (20080101), pages 34 - 48, (20080101), XP023783720 [X] 1,7-9,13-15 * paragraph [03.7] *
SEARCH- OKLU R ET AL, "Expression of alternatively spliced human latent transforming growth factor beta binding protein-1", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19980918), vol. 435, no. 2-3, doi:10.1016/S0014-5793(98)01054-0, ISSN 0014-5793, pages 143 - 148, XP004258319 [X] 1,7-9,13-15 * abstract *
SEARCH- NUNES I ET AL, "LATENT TRANSFORMING GROWTH FACTOR-BETA BINDING PROTEIN DOMAINS INVOLVED IN ACTIVATION AND TRANSFLUTAMINASE-DEPENDENT CROSS-LINKINGOF LATENT TRANSFORMING GROWTH FACTOR-BETA", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, (19970310), vol. 136, no. 5, doi:10.1083/JCB.136.5.1151, ISSN 0021-9525, pages 1151 - 1163, XP000680352 [X] 1,7-9,13-15 * abstract * * page 1158 *
SEARCH- KWAK JOON HYEOK ET AL, "Expression and regulation of latent TGF-beta binding protein-1 transcripts and their splice variants in human glomerular endothelial cells", JOURNAL OF KOREAN MEDICAL SCIENCE, (200508), vol. 20, no. 4, ISSN 1011-8934, pages 628 - 635, XP002761963 [X] 1,7-9,13-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents